We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Secondary Adjuvant Long Term Study With Arimidex (SALSA)

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00295620
First Posted: February 24, 2006
Last Update Posted: July 5, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AstraZeneca
  Purpose
The study assesses the effect of further 2 years vs further 5 years of adjuvant treatment with anastrozole after initial 5 years of adjuvant endocrine therapy.

Condition Intervention Phase
Breast Cancer Drug: Anastrozole Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Open, Multicentre Phase III-study to Assess the Efficacy of Secondary Adjuvant Endocrine Anastrozole Therapy for 2 Further Yrs vs 5 Further Yrs in Patients With HR +ve Breast Cancer After 5-yr Primary Adjuvant Endocrine Therapy

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Assessment of the effect in terms of DFS of 2 further years of anastrozole treatment vs further 5 years of adjuvant anastrozole treatment, following 5 years of adjuvant endocrine treatment [ Time Frame: throughout study (approx 15 years) ]
    Proof of the effect of 2 years versus 5 years of Anastrozol after 5 years of adjuvant endocrine therapy on the disease free survival


Secondary Outcome Measures:
  • Assessment of overall survival rate, rate of fracture occurrence, occurrence of secondary carcinoma and contralateral breast cancer in the two treatment groups [ Time Frame: throughout study (approx 15 years) ]
    1. Proof of the effect of 2 years versus 5 years of Anastrozol after 5 years of adjuvant endocrine therapy on the overall survival
    2. Comparison of fracture rate in both therapy groups
    3. Comparison of incidence of

      1. a secondary carcinoma except the contralateral mammacarcinoma
      2. contralateral mammacarcinoma in both therapie groups


Enrollment: 3486
Actual Study Start Date: March 1, 2004
Estimated Study Completion Date: December 31, 2020
Estimated Primary Completion Date: December 31, 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A: Anastrozol
1 mg per day for 2 years
Drug: Anastrozole
1mg tablet daily
Other Name: Arimidex
Experimental: Arm B: Anastrozol
1 mg per day for 5 years
Drug: Anastrozole
1mg tablet daily
Other Name: Arimidex

Detailed Description:

ABCSG 16 S.A.L.S.A is assessing the effect of further 2 years vs further 5 years of adjuvant treatment with anastrozole after initial 5 years of adjuvant endocrine therapy. S.A.L.S.A. is a randomized open multicentered phase III study comparing the efficacy of secondary adjuvant endokrine treatment of Arimidex® (Anastrozol) for 2 or 5 years after primary adjuvant endokrine therapy in patients with hormonreceptor positive mammakarzinom. Patients are examined at screening, after 6 months, then every year until 5 years. The subsequent yearly follow up with mammographie and clinical examination ends 10 years after the screening. S.A.L.S.A. started in February 2004 and has recruited 3484 patients until June 2010 at 78 sites all over Austria.

Primary Endpoint:

1. Proof of the effect of 2 years versus 5 years of Anastrozol after 5 years of adjuvant endocrine therapy on the disease free survival

Secondary endpoint:

  1. Proof of the effect of 2 years versus 5 years of Anastrozol after 5 years of adjuvant endocrine therapy on the overall survival
  2. Comparison of fracture rate in both therapy groups
  3. Comparison of incidence of

    1. a secondary carcinoma except the contralateral mammacarcinoma
    2. contralateral mammacarcinoma in both therapie groups
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 80 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. Postmenopausal patients with histologically confirmed, local radically treated invasive or minimal-invasiv Mammacarcinom with or without previous chemotherapie and/or radiotherapie.
  2. No distant metastasis at randomization
  3. No relapse at randomization
  4. TNM- classification at time of diagnosis: T1-3, N0 and N+, M0
  5. Estrogen- and or progesterone positive before the beginningof primary endocrine therapy
  6. Endocrine therapy for 5 years (maximum deviation ±12 months)
  7. Therapy break (from the preliminary therapie) maximum 12 months.
  8. Informed Consent before the randomisation

Exclusion criteria:

  1. Premenopausal patients or patients with non definable menopausal statusat time of randomisation
  2. Apparent secondary malignant tumor or status after secondary malignant tumor (Exceptions: simultaniously appearing bilateral breast carcinoma, estrogen- and or progesteronereceptor positive on both sides at the time of diagnosis; in situ carcinomaof the cervix and basal cell carcinoma of the skin)
  3. General contraindication respectively hypersensitivity to Anastrozol.
  4. In-situ carcinoma of any size with or without Mb. Paget of the Mamilla respectively T4 tumor at the time of first diagnosis.
  5. Receptor unknown or negative at time of diagnosis respectively at beginning of primary endocrine therapy
  6. Known liver- and/or kidneyinsufficiency
  7. Performance Index >2 according to WHO
  8. Regular intake of hormon supplement as well as Hormone Replacement Therapy (HRT) more than 6 months since primary surgery of the mamma carcinoma
  9. Serious accessory disease, that prevents the adjuvant therapy according to protocol and/or the regular follow-up care.
  10. Lacking compliance of the patient
  11. Legal incompetence and/or other circumstances, that prevent the patient from understanding the nature, meaning and consequences of the clinical trial
  12. Existing psychiatrical diseaseaccording to ICD (especially alcohol addiction) et the time of admission into the study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00295620


  Show 62 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: AstraZeneca Austria Medical Director, MD AstraZeneca
  More Information

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00295620     History of Changes
Other Study ID Numbers: 1033AU/0003
ABCSG 16
D5392L00016
SALSA
First Submitted: February 23, 2006
First Posted: February 24, 2006
Last Update Posted: July 5, 2017
Last Verified: July 2017

Keywords provided by AstraZeneca:
Hormone receptor positive breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Anastrozole
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs